Work

Abstract B045: ATX-559, a first-in-class, clinical-stage DHX9 inhibitor, as a targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-b045

Authors: Sunaina Nayak, Jennifer Castro, Monique Laidlaw, Priya Rajaratnam, Maureen Lynes, Stuart Ince, Jason A. Sager, Serena J. Silver

Institution: Accent Therapeutics (United States)

Language: English

Topic: DNA Repair Mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415444563

Cites:

Cited by:

Related to: